Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer

Withdrawn before enrolling · Phase 1

Conditions studied: Cervical Cancer

In brief

Investigator has since decided not to pursue this protocol further. No patients were enrolled. This study is to determine the maximum tolerated dose of external beam radiation to the para-aortic lymph nodes using intensity modulated radiation therapy (IMRT). This protocol will test the hypothesis that the use of IMRT and amifostine will decrease GI toxicity and therefore allow the radiation dose to the para-aortic lymph nodes to be safely escalated.

Key facts

Study ID

NCT00137358

Run by

University of Alabama at Birmingham

People needed

0

Last updated by the study team

2013-01-24

Who can join

Age: 19 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• No prior therapy other than biopsy of the cervix or endoscopic pelvic nodal resection.
• Patients may have endoscopic resection of enlarged pelvic and low common iliac nodes, however, needle biopsy only of enlarged para-aortic nodes will be eligible for entry.
• Patients with squamous cell, adenocarcinoma, and adenosquamous carcinoma are eligible.
• Patients must have no evidence of metastatic disease outside of the pelvis (except to the para-aortic nodes).
• Patients must have Zubrod performance status 0-1 and no medical contraindications to the administration of full dose chemotherapy.
• Patients must have a life expectancy > 6 months
• Adequate bone marrow function: white blood cell (WBC) 3000/mm3 (absolute neutrophil count [ANC] 1500/mm3); adequate renal function: creatinine 1.5 mg/dl (urinary diversion is permitted to improve renal function); patients must have bilirubin 1.5 mg/dl, ALT 2 x normal.
• No prior (within last 3 years) or simultaneous malignancies (other than basal cell or non-invasive tumors)

You may not qualify if…

• Complete resection of the involved para-aortic nodes.
• Patients with evidence of bowel adherent to the GTV by contrast enhanced computed tomography (CT) scan will be ineligible.
• Patients with the following histologies will be ineligible: glassy cell, small cell, carcinoid, adenoid cystic, and clear cell.
• Prior (within last 3 years) malignancies other than basal cell carcinoma or non-invasive malignancies.
• Prior chemotherapy.
• Prior pelvic or abdominal radiation (other than transvaginal irradiation to control bleeding).
• Prior tumor-directed surgery other than lymph node sampling/staging
• Life expectancy < 6 months
• Patients who are pregnant will be ineligible.
• Patients with insulin dependent diabetes will be ineligible.
• Patients who are obese, such that reliable immobilization is not achieved.
• Patients with pain or discomfort that would preclude lying still for extended periods of time.
• Patients with tumors that are bleeding and require more immediate treatment.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.